InvestorsHub Logo
Followers 800
Posts 50869
Boards Moderated 2
Alias Born 12/12/2004

Re: subslover post# 59

Tuesday, 12/06/2022 4:33:26 PM

Tuesday, December 06, 2022 4:33:26 PM

Post# of 186
Congrats! Nice run on todays news.
Summit Therapeutics announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific antibody, ivonescimab.

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SMMT News